Brain alterations and clinical symptoms of dementia in diabetes: Aβ/tau-dependent and independent mechanisms

Naoyuki Sato1,2* and Ryuichi Morishita1

1 Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan
2 Department of Geriatric Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan

Emerging evidence suggests that diabetes affects cognitive function and increases the incidence of dementia. However, the mechanisms by which diabetes modifies cognitive function still remains unclear. Morphologically, diabetes is associated with neuronal loss in the frontal and temporal lobes including the hippocampus, and aberrant functional connectivity of the posterior cingulate cortex and medial frontal/temporal gyrus. Clinically, diabetic patients show decreased executive function, information processing, planning, visuospatial construction, and visual memory. Therefore, in comparison with the characteristics of AD brain structure and cognition, diabetes seems to affect cognitive function through not only simple AD pathological feature-dependent mechanisms but also independent mechanisms. As an Aβ/tau-independent mechanism, diabetes compromises cerebrovascular function, increases subcortical infarction, and might alter the blood–brain barrier. Diabetes also affects glucose metabolism, insulin signaling, and mitochondrial function in the brain. Diabetes also modifies metabolism of Aβ and tau and causes Aβ/tau-dependent pathological changes. Moreover, there is evidence that suggests an interaction between Aβ/tau-dependent and independent mechanisms. Therefore, diabetes modifies cognitive function through Aβ/tau-dependent and independent mechanisms. Interaction between these two mechanisms forms a vicious cycle.

Keywords: dementia, diabetes mellitus, Alzheimer disease, abeta, tauopathies

INTRODUCTION

More than 30 million patients suffer from dementia (1), while 285 million battle diabetes in this aging society (2). Emerging evidence suggests that diabetes increases the incidence of dementia (3–8). Indeed, diabetes in mid-life is associated with mild cognitive impairment (MCI) (3), and impaired glycemia increases disease progression to dementia in patients with MCI (4). Moreover, numerous epidemiological studies have also demonstrated that patients with diabetes have a significantly higher risk of developing AD (5–8). While genetic and non-genetic risk factors contribute to sporadic AD (9), APOEε4 is the strongest genetic risk factor for sporadic AD and is believed to promote the development of senile plaques. However, the mechanisms by which diabetes modifies cognitive function still remain unclear (10). Here, we review recent advances in brain alterations and clinical symptoms in dementia associated with diabetes and its Aβ/tau-dependent and independent mechanisms.

BRAIN ALTERATIONS IN DEMENTIA ASSOCIATED WITH DIABETES

Diabetes causes functional and structural deficits in the brain (Table 1). Diabetes is associated with reduced volume of the hippocampus (3, 11), whole brain (3), gray (12), and white matter (11). Gray matter loss is distributed in the medial temporal, anterior cingulate, and medial frontal lobes (3, 11, 12), and white matter loss occurs in the frontal and temporal regions (11), whereas, in AD, gray matter loss is in temporal lobe, hippocampus, entorhinal, and parietal lobes (13–15), and white matter loss is in the temporal region (16). In addition to neuronal loss, diabetes also affects functional connectivity. Resting-state functional connectivity, measured by functional MRI, is used to access brain function. Disruption of resting-state functional connectivity in the default mode network, which is most active during rest, is recently believed to be a predictor of current and future cognitive dysfunction, especially in AD (17, 18). Diabetic patients develop aberrant functional connectivity of the posterior cingulate cortex with the medial temporal gyrus (19) and medial frontal gyrus (20), reflecting white matter abnormalities in diabetes. Diabetic patients also have decreased spontaneous brain activity in the occipital lobe and postcentral gyrus (21). Moreover, functional MRI during task performance demonstrates that diabetic patients show reduced activation of the dorsolateral prefrontal cortex during encoding (22). These studies suggest that diabetes is associated with neuronal loss in the frontal and temporal lobes including the hippocampus, and aberrant functional connectivity between the posterior cingulate cortex and medial frontal/temporal gyrus.

Abbreviations: AMPK, AMP-activated protein kinase; APP, amyloid precursor protein; BBB, blood–brain barrier; IGF-1, insulin-like growth factor-1; IRS-2, insulin receptor substrate-2; MCI, mild cognitive impairment; RAGE, receptor for advanced glycation endproducts.
Table 1 | Comparison of brain structural and functional alteration in diabetes and Alzheimer disease.

| Structural change | Diabetes | Alzheimer disease |
|-------------------|----------|------------------|
| Gray matter loss  | Frontal, temporal lobes, hippocampus (3, 11, 12), anterior cingulate cortex (11) | Temporal lobe, hippocampus, entorhinal, and parietal lobes (13–15) |
| White matter loss | Frontal and temporal regions (11) | Temporal region (16) |

| Functional change | Aberrant functional connectivity | Decreased spontaneous brain activity | Task-induced brain activity |
|-------------------|---------------------------------|------------------------------------|-----------------------------|
|                   | Between posterior cingulate cortex and medial frontal (20)/temporal (19) gyrus | Occipital lobe and postcentral gyrus (21) | Reduced activation of dorsolateral prefrontal cortex during encoding and deactivation of default mode network during recognition (23) |

Table 2 | Comparison of cognitive and behavioral alterations in diabetes and Alzheimer disease.

| Cognitive function | Diabetes | Alzheimer disease |
|--------------------|----------|------------------|
| Memory             | Decreased (28) | Decreased (31, 32) |
| Attention           | Decreased (26, 27) | Decreased (31, 32) |
| Executive function | Decreased (28, 29) | Decreased (32) |
| Information processing | Decreased (28, 29) | Decreased (33), but less in initial phase |
| Planning           | Decreased (11) | Decreased (34) |
| Visual memory      | Decreased (11, 21) | Decreased (35, 36) |

| Behavioral psychological symptom | Apathy | Overeating | Excessive daytime sleeping |
|-----------------------------------|--------|-----------|---------------------------|
| Diabetes                          | Increased (30) | Increased (39), but less in initial phase | Increased (40) |
| Alzheimer disease                  | Increased (38) | Decreased (37) | Decreased (41) |

| Activity of daily living | Diabetes | Alzheimer disease |
|--------------------------|----------|------------------|
| –                        | Decreased (30) | Decreased (41) |

CLINICAL SYMPTOMS IN DEMENTIA ASSOCIATED WITH DIABETES

Diabetic patients show impaired cognitive function, increased behavioral symptoms, and decreased activity of daily living (Table 2). Diabetic patients show impairment of memory (25), attention (26, 27), executive function (28, 29), information processing (28, 29), planning (11), visuospatial construction (11), and visual memory (11, 21). Diabetic patients are reported to have impaired memory retrieval rather than encoding (25). Patients with higher HbA1c have increased behavioral and psychological symptoms (30) such as apathy, overeating, and excessive daytime sleeping, and also have impaired activities of daily living (30). Therefore, the knowledge about brain alterations and clinical symptoms suggests that diabetes affects cognitive function through not only simply AD pathological feature-dependent mechanisms but also independent mechanisms (Figure 1).

ALZHEIMER PATHOLOGICAL FEATURE-INDEPENDENT MECHANISMS

VASCULAR MECHANISM

Cerebrovascular damage is related to cognitive function (42–45) and brain atrophy (46). Diabetes is associated with vascular reactivity impairment (47, 48), microangiopathy (49), and cerebrovascular lesions (50), including subcortical infarcts (3). Indeed, microvascular network alteration in the retina, which is believed to be a predictor of vascular changes inside the brain, is associated with increased risk of cognitive dysfunction (51) and AD (52) in diabetes. Vascular permeability is reported to be increased in diabetic retinopathy (53), suggesting that diabetes disrupts the blood–brain barrier (BBB) inside the brain. These data suggest that diabetes compromises cerebrovascular function, increases subcortical infarction, and might cause BBB dysfunction.

METABOLIC MECHANISM

Hyperglycemia and hypoglycemia – brain glucose metabolism

Hyperglycemia and hypoglycemia have impacts on cognitive function and activity of daily life. Interestingly, Holmes et al. demonstrated that attention and fine motor skills were slowed at altered glucose levels, assessed in diabetic patients during hypoglycemia and hyperglycemia induced by an artificial insulin/glucose infusion system (27). In the long term, the duration of diabetes is associated with impaired cognition in patients with higher HbA1c levels (54). Glucose metabolism declines with age in many brain regions (55), and glucose hypometabolism and brain atrophy are associated with concurrent cognitive dysfunction (56).

Hypoglycemia is associated with cognitive impairment in elderly diabetic patients (57). Because the brain uses mainly glucose as an energy source, hypoglycemia causes defects of neuronal function, though lactate can also be used in such situations (58, 59). In addition to dysfunction of individual cells, failure of neuronal networking also contributes to cognitive impairment in a hypoglycemic state (60). In the long term, repeated
episodes of severe hypoglycemia are reported to also be a risk for the development of dementia (61). Hyperglycemia affects cognitive function, and is associated with brain hypometabolism (62), impaired deactivation of the default mode network (22), poorer memory, and reduced hippocampal microstructures (63). Behavioral and psychological symptoms, including apathy, overeating, and excessive daytime sleeping, appear to be increased in patients with HbA1c ≥7.0% (30). In an animal model, hyperglycemia induced by a high-fat diet causes chronic energy imbalance with resulting loss of neurons and reduces olfactory learning (64). These studies suggest that hyperglycemia has an impact on cognition and behavior through glucose-energy imbalance. Although the memory in diabetes (MIND) sub-study of action to control cardiovascular risk in diabetes (ACCORD) suggests that intensive glycemic control has no effect on cognitive function (65), the incidence of hypoglycemia should be considered in interpreting the data (66).

Hyperinsulinemia – brain insulin signaling

Insulin signaling is believed to be decreased in the diabetic brain. Insulin receptors are expressed in the cortex and hippocampus (67–69), and peripheral insulin accesses the brain by crossing the BBB (70). Insulin is also produced in the CNS. Indeed, single-cell PCR reveals that insulin is strongly expressed in GABAergic neuregliaform cells in the cerebral cortex (71). Similarly, insulin-like growth factor-1 (IGF-1), IGF-2, and their receptors exist in the CNS (72–75). When insulin binds to the insulin receptor, IRS-1 and -2 (insulin receptor substrate) undergo tyrosine phosphorylation and bind phosphatidylinositol 3-kinase (PI3K) (76), which activates AKT and glycogen-synthase kinase-3β (GSK3β) (77–79). Importantly, insulin receptor knockout mice show no obvious alteration in the brain (80), suggesting compensation of IGF receptor signaling for insulin signaling. Liu also reported that the levels and activities of several components of the insulin–PI3K–AKT signaling pathway were decreased in patients with diabetes (81). Taken together, these findings indicate that insulin/IGF signaling is impaired in the diabetic brain, and this signaling might have an impact on aging-related brain dysfunction (82). Interestingly, aerobic exercise increases some proteins related to the insulin/IGF-1 pathway in the hippocampus and improves spatial memory in diabetic rats (83).

Brain mitochondrial metabolism

Diabetes deregulates mitochondrial function in mouse (84) and rat (85) neurons. Recent work reveals that hyperglycemia mediates a phenotypic change in mitochondrial biology through alteration of AMP-activated protein kinase (AMPK), a key cellular energy sensor that regulates the activity of a number of metabolic enzymes (86). It is known that an anti-diabetic drug, metformin, activates AMPK kinase. These findings might explain the recent clinical observation that use of metformin is associated with increased risk of cognitive impairment in patients with diabetes (87), though this is still controversial (88). Diabetes is also reported to impair neurite outgrowth through JAK/STAT3 modulation of mitochondrial bioenergetics in neurons (89). Thus, mitochondria might be a new therapeutic target not only for diabetic neuropathy (90) but also for dementia associated with diabetes.

ALZHEIMER PATHOLOGICAL FEATURE-DEPENDENT MECHANISMS

Aβ-DEPENDENT MECHANISM

While AD consists of both familial and sporadic forms, familial AD is caused by mutations in the amyloid precursor protein (91) and presenilin (92). Both mutations cause overproduction of Aβ, particularly its longer form, Aβ42, which is more prone to aggregate in vitro (93) and deposits first in the brain (94) to form senile plaques. Insulin resistance in mid-life is associated with the development of senile plaques (8), though retrospective studies suggest that the magnitude of senile plaques and another hallmark, neurofibrillary tangles, is comparable between AD with and without diabetes (95). Several groups report that a high-fat diet causes Aβ accumulation in the brain of wild type rabbits (96) and APP Tg mice (97, 98). Accumulation of autophagosomes to enhance amyloidogenic APP processing (99) or up-regulation of BACE1 (100) have thus far been proposed as the mechanisms of the increase in Aβ by diabetes. APP+/ob/ob mice, produced by crossing of diabetic and obese ob/ob mice, manifest no change in total brain Aβ level, but increase Aβ deposition in the cerebral vasculature (101). APP+/ob/ob mice show up-regulation of RAGE, the receptor for AGE (102), in the vasculature. Because RAGE mediates amplification of inflammatory responses (103), inflammatory cytokines are upregulated around the cerebrovasculature in APP+/ob/ob (101). Soluble Aβ itself is believed to reduce endothelial function in vitro (27) and vascular reactivity in mice (104) and humans (105, 106). Interestingly, crossing obese and diabetic db/db mice with APP/PS1 knock-in mice leads to severe cerebrovascular pathological features, including aneurysms and small strokes, though no further Aβ deposition in the vasculature, indicating an interaction between soluble Aβ and a diabetic vascular factor (107).

Glucose-energy metabolism is altered in AD (108) and various AD models (109–111). Amyloid burden is accompanied by glucometabolic increases in people at risk for AD (108). Brain 18FDG uptake is a sensitive biomarker for early detection of abnormal metabolism in the 5XFAD mouse (109), indicating that glucose metabolism is decreased in the AD model brain. A glucose transporter, Glut-1, is reduced in the brain capillaries
of 18-month-old 3xTg-AD mice (110), suggesting that glucose uptake into the brain might be altered. Another AD model, APP/PS1 mice, also shows alterations in energy-sensor AMPK (111). AMPK could mediate the toxic effects of Aβ through tau phosphorylation (112).

Insulin signaling is also altered by Aβ. In the AD brain, the levels of insulin and IGF (113) and the responses to insulin and IGF (114) are reduced. The levels and activities of the insulin signaling pathway are also decreased in AD (81, 115) and diabetic brains (81), as mentioned above. AD animal models show significant reductions in insulin receptor (111), IRS-1 (116), and IRS-2 (111) in the brain. Therefore, diabetes and Aβ could synergistically affect insulin signaling (101, 117, 118). This impaired insulin signaling could lead to an increase of tau phosphorylation.

**Tau-DEPENDENT MECHANISM**

Diabetes could promote tau phosphorylation, and then formation of neurofibrillary tangles, which is one of the major pathological features of AD. Normal tau promotes the assembly and stabilization of microtubules, but abnormally hyperphosphorylated tau sequesters normal tau and disrupts microtubules (119, 120). Several neuropathological studies suggest that the magnitude of neurofibrillary tangles in the brain at autopsy is not different between AD with and without diabetes (95). However, animal studies show that tau phosphorylation is increased in diabetes (121–125). Tau phosphorylation is increased in the cortex and hippocampus in db/db mice (121) and streptozotocin-induced diabetic mice (122–124). Moreover, streptozotocin exacerbates neurofibrillary tangles in a transgenic mouse model over-expressing the P301L mutant human tau (125). Recently, Takalo et al. report that a high-fat diet induces the expression of four repeat tau mRNA and protein in the temporal cortex (126). Importantly, tau phosphorylation sites in AD are shown to be increased in the diabetic human brain (127). These data suggest that diabetes promotes tau phosphorylation, splicing, and the formation of neurofibrillary tangles.

Impaired insulin signaling in the brain could cause tau phosphorylation (128) and insulin signaling is mainly mediated through the PI3K–Akt–GSK3β pathway (77–79). Because GSK3β phosphorylates tau, insulin inhibits tau phosphorylation through negative regulation of GSK3β (129). Therefore, loss of insulin (130), insulin receptor (80), or IRS-2 (131–133) increases tau phosphorylation. While protein phosphorylation is also regulated by kinases and phosphatases, tau is reported to be dephosphorylated by protein phosphatase 2A (PP2A) (134). As disruption of IRS-2 downregulates PP2A (134), impaired insulin signaling might cause tau phosphorylation by influencing not only kinases but also phosphatases. Importantly, depletion of endogenous tau mitigates behavioral impairment and synaptic deficits induced in diabetic mice (135). Taken together, these findings indicate that diabetes could promote tau phosphorylation via impaired insulin signaling in the brain and then, contribute to cognitive impairment.

**CONCLUSION**

Morphologically, diabetes is associated with neuronal loss in the frontal and temporal lobes including the hippocampus, and aberrant functional connectivity of the posterior cingulate cortex and medial frontal/temporal gyrus, and decreased spontaneous brain activity in the occipital lobe and postcentral gyrus. As clinical symptoms, diabetic patients show decreased executive function, information processing, planning, visuospatial construction, and visual memory. Therefore, in comparison with the characteristics in AD brain structure and cognition, diabetes seems to affect cognitive function through not only simply AD pathological feature-dependent but also independent mechanisms. As Aβ/tau-independent mechanisms, diabetes compromises cerebrovascular function, increases subcortical infarction, and might alter BBB. Diabetes also compromises glucose metabolism, insulin signaling, and mitochondrial function. Diabetes also modifies metabolism of Aβ and tau and causes Aβ/tau-dependent pathological changes. Interestingly, in cognitively normal diabetic subjects, higher mean HbA1c levels are associated with lower cognitive performance in ApoE4 carriers (136), indicating an interaction between Aβ/tau-dependent and independent mechanisms. In conclusion, diabetes modifies cognitive function through Aβ/tau-dependent and independent mechanisms. Interaction between these two mechanisms forms a vicious cycle.

**ACKNOWLEDGMENTS**

We greatly acknowledge grants from Japan Promotion of Science and the Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant-in-Aid for Scientific Research (B) No. 26293167; to Naoyuki Sato). We also thank members of Department of Clinical Gene Therapy and Department of Geriatric Medicine, past and present.

**REFERENCES**

1. Dartigues JF. Alzheimer’s disease: a global challenge for the 21st century. Lancet Neurol (2009) 8(12):1082–3. doi:10.1016/S1474-4422(09)70298-4
2. Type 2 diabetes epidemic: a global education. Lancet (2009) 374(9702):1654. doi:10.1016/S0140-6736(09)61974-7
3. Roberts RO, Knope DN, Przybelski SA, Mielke MM, Kantarcı K, Presboke GM, et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology (2014) 82(13):1326–41. doi:10.1212/WNL.0000000000008269
4. Morris JK, Vidoni ED, Honea RA, Burns JM. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging (2014) 35(3):585–9. doi:10.1016/j.neurobiolaging.2013.09.033
5. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer’s disease. Expert Rev Neurother (2009) 9(5):617–30. doi:10.1586/ern.09.18
6. Kopf D, Frollich L. Risk of incident Alzheimer’s disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis (2009) 16(4):677–85. doi:10.3233/JAD-2009-1011
7. Ott A, Stökl RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology (1999) 53(9):1937–42. doi:10.1212/WNL.53.9.1937
8. Matsuazaki T, Sasaki K, Tanizaki Y, Hata J, Fujiimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology (2010) 75(9):764–70. doi:10.1212/WNL.0b013e3181ee25f
9. Fotuhi M, Harchinski V, Whitehouse PL. Changing perspectives regarding late-life dementia. Nat Rev Neurol (2009) 5(12):649–58. doi:10.1038/nrneurol.2009.175
10. Sato N, Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci (2013) 5:64. doi:10.3389/fnagi.2013.00064
11. Moran C, Phan TG, Chen J, Blizard L, Beare R, Venn A, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care (2013) 36(12):4036–42. doi:10.2337/dc13-0143
12. Garcia-Casares N, Berthier ML, Jorge RE, Gonzalez-Alegre P, Gutiérrez Cardo A, Rojas Villosladas J, et al. Structural and functional brain changes in middle-aged type 2 diabetic patients: a cross-sectional study. *J Alzheimers Dis* (2014) 40(2):375–86. doi:10.3233/JAD-131736

13. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* (1991) 82(4):239–59. doi:10.1007/BF00380889

14. Thompson PM, Hayashi KM, de Zubicaray GJ, Lanke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer’s disease. *J Neurosci* (2003) 23(3):994–1005.

15. Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, da Silva CG, Guimarães DM, Szczupak D, et al. Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. *Brain* (2013) 136(Pt 12):3738–52. doi:10.1093/brain/awt273

16. Mann DM. The topographic distribution of brain atrophy in Alzheimer’s disease. *Acta Neuropathol* (1991) 83(1):81–6. doi:10.1007/BF02944343

17. Buckner RL, Snyder AZ, Shannon BI, LaRossa G, Sachs R, Fotenos AE, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. *J Neurosci* (2005) 25(34):7907–19. doi:10.1523/JNEUROSCI.2177-05.2005

18. Sorg C, Riedl V, Mihula M, Calhoun VD, Eichele T, Läer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer’s disease. *Proc Natl Acad Sci U S A* (2007) 104(47):18760–5. doi:10.1073/pnas.0708803104

19. Chen YC, Jiao Y, Cui Y, Wang SC, Deng J, Feng Y, et al. Ablation brain functional connectivity related to insulin resistance in type 2 diabetes: a resting-state fMRI study. *Diabetes Care* (2014) 37(6):E189–96. doi:10.2337/dc13-1217

20. Hoogenboom WS, Marder TJ, Flores VL, Huisman S, Eaton HP, Schneiderman JS, et al. Cerebral white matter integrity and resting-state functional connectivity in middle-aged patients with type 2 diabetes. *Diabetes* (2014) 63(2):728–38. doi:10.2337/db13-0519

21. Cui Y, Jiao Y, Chen YC, Wang K, Gao B, Wen S, et al. Altered spontaneous brain activity in type 2 diabetes: a resting-state functional MRI study. *Diabetes* (2014) 63(2):749–60. doi:10.2337/db13-1219

22. Marder TJ, Flores VL, Bolo NR, Hoogenboom WS, Simonson DC, Jacobson AM, et al. Task-induced brain activity patterns in type 2 diabetes: a potential biomarker for cognitive decline. *Diabetes*. (2014). doi:10.2337/db13-1783

23. Wang Z, Yan C, Zhao C, Qi Z, Zhou W, Lu J, et al. Spatial patterns of intrinsinc brain activity in mild cognitive impairment and Alzheimer’s disease: a resting-state functional MRI study. *Hum Brain Mapp* (2011) 32(10):1720–40. doi:10.1002/hbm.21140

24. Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR, et al. A biomarker for cognitive decline. *J Neurosci* (2014) 34(4):288–94. doi:10.1159/000345157

25. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson’s disease. *Brain* (1988) 111(Pt 3):695–718. doi:10.1093/brain/111.3.695

26. Mori T, Shimada H, Shinozoh H, Hirano S, Eguchi Y, Yamada M, et al. Apa- tory correlates with prefrontal amyloid beta deposition in Alzheimer’s disease. *J Neurol Neurosurg Psychiatry* (2014) 85(4):449–55. doi:10.1136/jnnp-2013-306110

27. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease, IV: disorders of behaviour. *Br J Psychiatry* (1990) 157:86–94. doi:10.1192/bjp.157.8.86

28. Rothman SM, Mattson MP. Sleep disturbances in Alzheimer’s and Parkinson’s diseases. *Neuromolecular Med* (2012) 14(3):194–204. doi:10.1007/s12017-012-0181-2

29. Patterson MB, Mack JL, Neundorffer MM, Martin RJ, Smyth KA, Whitehouse PJ. Assessment of functional ability in Alzheimer disease: a review and a preliminary report on the Cleveland scale for activities of daily living. *Alzheimer Dis Assoc Disord* (1992) 6(3):145–63. doi:10.1002/0002-0093(19920630)01:STR.27.3.408

30. Ladeoca C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertonie. *Stroke* (2009) 40(3 Suppl):540–4. doi:10.1161/STROKEAHA.108.533638

31. Dickstein DL, Walsh J, Braittgum H, Stockton SD Jr, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. *Mt Sinai J Med* (2010) 77(1):82–102. doi:10.1002/mus.20355

32. Neltner JH, Abner EL, Baker S, Schmitt FA, Kryscio RJ, Jicha GA, et al. Arteriosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. *Brain* (2014) 137(Pt 1):255–67. doi:10.1093/brain/awt318

33. Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer’s patients? *J Alzheimers Dis* (2012) 32(3):765–72. doi:10.3233/JAD-2012-121012

34. Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, et al. Vascular and Alzheimer’s disease markers independently predict brain atrophy rate in Alzheimer’s disease neuroimaging initiative controls. *Neurobiol Aging* (2013) 34(8):1996–2002. doi:10.1016/j.neurobiaging.2013.02.005

35. Caballero AE, Arora S, Saouaf R, Lima SC, Smukowski P, Park YJ, et al. Microvas- cular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. *Diabetes* (1999) 48(9):1856–62. doi:10.2337/diabetes.48.9.1856

36. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. *Diabetes Metab* (2006) 32(5 Pt 1):403–14. doi:10.1016/S1262-3636(07)70927-9

37. Munn DM, Houben AJ, Schram MT, Stehouwer CD. Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. *Arterioscler Thromb Vasc Biol* (2012) 32(12):3082–94. doi:10.1161/ATVBAHA.112.300291

38. van Elderen SG, de Roos A, de Craen AJ, Westendorp RG, Blauw GJ, Jukema JW, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus:
Sato and Morishita The mechanisms of dementia in diabetes

67. Havranova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. *Nature* (1978) 272:15636; 827–9. doi:10.1038/272827a0

68. Wiglewicz I. Tracking insulin to the mind. *Science* (1998) 280:5363; 517–9. doi:10.1126/science.280.5363.517

69. Hill JM, Lesnai MA, Pert CB, Roth J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. *Neuroscience* (1986) 17(4):1127–38. doi:10.1016/0306-4522(86)90082-5

70. Banks WA. The source of cerebral insulin. *Eur J Pharmacol* (2004) 490(1–3):5–12. doi:10.1016/j.ejphar.2004.02.040

71. Molnar G, Faraghi N, Kocsis AK, Rioza M, Lovoas S, Boldog E, et al. GABAergic neurogliaform cells represent local sources of insulin in the cerebral cortex. *Neurosci* (2014) 34(4):1133–7. doi:10.1523/JNEUROSCI.4802-13.14.2014

72. Shemer J, Raizada MK, Masters BA, Ota A, LeRoith D. Insulin-like growth factor I receptors in neuronal and glial cells. Characterization and biological effects in primary culture. *J Biol Chem* (1987) 262(16):7693–9. doi:10.1016/0022-2837(87)905066-7

73. Araujo DM, Latchak PA, Collier B, Chabot JG, Quirion R. Insulin-like growth factor-1 (somatomedin-C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system. *Brain Res* (1989) 48(1–2):130–8.

74. Rotwein P, Burgess SK, Milbrandt JD, Kraje RE. Differential expression of insulin-like growth factor genes in rat central nervous system. *Proc Natl Acad Sci U S A* (1985) 82(1):265–9. doi:10.1073/pnas.82.1.265

75. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebini B, Pollonini G, Bambhia M, et al. A critical role for IGF-II in memory consolidation and enhancement. *Nature* (2011) 469(7311):491–7. doi:10.1038/nature09667

76. Sherer T, Raizada MK, Masters BA, Wei Y, Baudier M, Schartner E, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. *Nature* (1991) 352(6360):73–7. doi:10.1038/352703a0

77. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. *Biochem J* (1993) 296(1 Pt 1):15–9.

78. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* (1995) 378(6559):785–9. doi:10.1038/378785a0

79. Neumann KF, Rojo L, Navarette LP, Farias G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. *Curr Alzheimer Res* (2008) 5(5):438–47. doi:10.2174/156720508785908919

80. Schubert M, Gautam D, Surjo D, Ueki K, Baudier M, Schubert D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. *Proc Natl Acad Sci U S A* (2004) 101(9):3100–5. doi:10.1073/pnas.030824101

81. Liu Y, Liu F, Grundke-Iqbal I, Ishibashi K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. *J Pathol* (2011) 225(1):54–62. doi:10.1002/path.2912

82. Steculorum SM, Solas M, Bruning JC. The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. *Alzheimers Dement* (2014) 10(1):Suppl S3:S1–S11. doi:10.1016/j.dementia.2013.12.008

83. Dieguès JC, Pauli JR, Luciano E, de Almeida Leme JA, de Moura LP, Dalia RA, et al. Spatial memory in sedentary and trained diabetic rats: molecular mechanisms. *Hippocampus* (2014) 24(6):703–11. doi:10.1002/hipo.22261

84. Edwards JL, Quattrini A, Lentz SI, Figueroa-Romero C, Cerri F, Backus C, et al. Diabetes regulates mitochondrial biogenesis and fusion in mouse neurons. *Diabetologia* (2013) 56(1):160–9. doi:10.1007/s00125-012-2569-3

85. Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Peroxisome proliferator-activated receptor gamma agonist improves neuronal insulin receptor function in hippocampus of insulin-resistant mice. *Eur J Pharmacol* (2013) 70.1:265–9. doi:10.1016/j.ejphar.2013.01.010

86. Berroa E, et al. The Association of duration of type 2 diabetes with cognitive elks associated with lower memory and reduced hippocampal microstructure. *Neurology* (2014) 83(5):352–6. doi:10.1212/WNL.000000000000342

87. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label study. *Lancet Neurol* (2011) 10(10):2981–7. doi:10.1016/S1474-4422(11)70889-0

88. Strachan MW, Price FE. The role of aberrant mitochondrial bioenergetics in diabetic neuropathy. *Neurobiol Dis* (2013) 51:56–65. doi:10.1016/j.nbd.2012.03.016

89. Moore EM, Mander AG, Ames D, Kotwicz MA, Carne RP, Brodaty H, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label study. *Lancet Neurol* (2011) 10(10):2981–7. doi:10.1016/S1474-4422(11)70889-0

90. Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL. Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. *Nat Clin Pract Neurol* (2006) 2(11):620–8. doi:10.1038/ncpneuro0630
91. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* (1991) 349(6311):704–6. doi:10.1038/349704a0

92. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* (1995) 375(6534):754–60. doi:10.1038/375754a0

93. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry* (1993) 32(18):4693–7. doi:10.1021/bi0100610

94. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and a beta 40 in senile plaques with end-specific A beta monoclonal evidence that an initially deposited species is A beta 42(43). *Neuron* (1994) 13(1):45–53. doi:10.1016/0896-6273(94)90458-8

95. Kalaria RN. Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease. *Nat Rev Neurol* (2009) 5(6):305–6. doi:10.1038/nrneurol.2009.72

96. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. *Exp Neurol* (1994) 126(1):88–94. doi:10.1006/exnr.1994.1044

97. Refolo LM, Malester B, LaFrancois I, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. *Diabetes Metab* (2000) 7(4):321–31. doi:10.2337/dbi.200.0366

98. Ho L, Qin W, Pomp ML, Xiang Z, Wang J, Zhao Z, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. *FASEB J* (2004) 18(7):902–4. doi:10.1096/fj.03-978f6

99. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, et al. Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. *Autophagy* (2012) 8(12). doi:10.4161/aut.21861

100. Guglielmetto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, et al. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. *Mol Biosyst* (2012) 8(10):e113–27. doi:10.1016/j.neurobiolaging.2012.05.026

101. Takeda S, Sato N, Uchio-Yamada K, Sowada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebral vascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. *Proc Natl Acad Sci U S A* (2010) 107(15):7036–41. doi:10.1073/pnas.100645107

102. Brownlee M, Cerami A, Vlassara H. Advanced glycation end products in tissue and the biochemical basis of diabetic complications. *N Engl J Med* (1988) 318(10):1351–21. doi:10.1056/NEJM198805193181007

103. Basta G, Lazzarini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. *Circulation* (2002) 105(7):816–22. doi:10.1161/01.01CIRC.104183

104. Niwa K, Younkin L, Ehinger C, Turner SW, Younkin S, et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatoanesthesia activation. *Proc Natl Acad Sci U S A* (2000) 97(17):9735–40. doi:10.1073/pnas.97.17.9735

105. Dumas A, Dierksen GA, Gurrol ME, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* (1991) 349(6311):704–6. doi:10.1038/349704a0

106. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* (1995) 375(6534):754–60. doi:10.1038/375754a0

107. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry* (1993) 32(18):4693–7. doi:10.1021/bi0100610

108. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and a beta 40 in senile plaques with end-specific A beta monoclonal evidence that an initially deposited species is A beta 42(43). *Neuron* (1994) 13(1):45–53. doi:10.1016/0896-6273(94)90458-8
128. El Khoury NB, Gratuz M, Papon MA, Bretteville A, Planel E. Insulin dysfunction and tau pathology. *Front Cell Neurosci* (2014) 8:22. doi:10.3389/fncel.2014.00022

129. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. *J Biol Chem* (1997) 272(31):19547–53. doi:10.1074/jbc.272.31.19547

130. Schechter R, Beju D, Miller KE. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. *Biochem Biophys Res Commun* (2005) 334(4):979–86. doi:10.1016/j.bbrc.2005.07.001

131. Freude S, Hettich MM, Schumann C, Stohr O, Koch L, Kohler C, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. *FASEB J* (2009) 23(10):3315–24. doi:10.1096/fj.09-132043

132. Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. *Biochem Biophys Res Commun* (2009) 386(1):257–62. doi:10.1016/j.bbrc.2009.06.032

133. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. *J Neurosci* (2003) 23(18):7084–92.

134. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A. *Neuron* (1996) 17(6):1201–7. doi:10.1016/S0896-6273(00)80250-0

135. Abbondante S, Baglietto-Vargas D, Rodriguez-Ortiz CJ, Estrada-Hernandez T, Medeiros R, Laferla FM. Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes. *Am J Pathol* (2014) 184(3):819–26. doi:10.1016/j.ajpath.2013.11.021

136. Ravona-Springer R, Heymann A, Schmeidler J, Sano M, Preiss R, Koifman K, et al. The ApoE4 genotype modifies the relationship of long-term glycemic control with cognitive functioning in elderly with type 2 diabetes. *Eur Neuropsychopharmacol* (2014) 24(8):1303–8. doi:10.1016/j.euroneuro.2014.05.001

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 11 July 2014; paper pending published: 07 August 2014; accepted: 15 August 2014; published online: 03 September 2014.

Citation: Sato N and Morishita R (2014) Brain alterations and clinical symptoms of dementia in diabetes: Aβ/tau-dependent and independent mechanisms. *Front. Endocrinol.* 5:143. doi: 10.3389/fendo.2014.00143

This article was submitted to Diabetes, a section of the journal *Frontiers in Endocrinology*.

Copyright © 2014 Sato and Morishita. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.